Role of inactivated SARS-CoV-2 vaccine induced T cell responses in ameliorating COVID-19 severity  

作　　者：Hongming Huang Jia Liu 

机构地区：[1]Department of Infectious Diseases,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430022,China [2]Joint International Laboratory of Infection and Immunity,Huazhong University of Science and Technology,Wuhan,430022,China

出　　处：《Virologica Sinica》2023年第2期324-326,共3页中国病毒学（英文版）

基　　金：supported by grants from the National Natural Science Foundation of China(82172256,92169105,81861138044,and M-0060);the National Scientific and Technological Major Project of China(2017ZX10202203);the Sino-German Virtual Institute for Viral Immunology.

摘　　要：The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)vaccine is one of the most effective weapons to fight the coronavirus disease 2019(COVID-19)pandemic(Lazarus et al.,2022).Among all SARS-CoV-2 vaccines generated on different platforms,those consisting of the inactivated virus,such as BBIBP-CorV and CoronaVac,have been frequently used(WHO,2023).By January 30,2023,92.9%of the entire,all-ages population had initiated vaccination and 90.6%had completed their primary series based on the whole population size reported in the seventh census of Chinese mainland(China CDC,2023).However,compared to SARS-CoV-2 mRNA vaccines,which can elicit extremely high quantities of anti-spike(S)antibodies,the levels of neutralizing antibodies induced by inactivated SARS-CoV-2 vaccines are quite lower and wane quickly(Peng et al.,2022;Lim et al.,2021).

关 键 词：VACCINE SEVERITY ACUTE 

分 类 号：R563.1[医药卫生—呼吸系统]